1.72 0.00 (0.00%)
After hours: 4:19PM EDT
|Bid||1.72 x 200|
|Ask||1.73 x 500|
|Day's range||1.59 - 1.76|
|52-week range||0.39 - 4.74|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2018 - 2 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||12.83|
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/255,901, “Quinoxalinyl Piperazinamide Methods of Use”. The allowed patent application covers the use of RX-5902, also known as Supinoxin for the treatment of cancers including triple negative breast cancer either as monotherapy or in combination with other anti-tumor agents such as cytotoxic agents or immune checkpoint inhibitors.
The Rockville, Maryland-based company said it had a loss of 4 cents per share. Losses, adjusted for non-recurring gains, came to 15 cents per share. The results topped Wall Street expectations. The average ...